Hikma Pharmaceuticals Share News (HIK)

0816 GMT [Dow Jones] UBS raises Hikma Pharmaceuticals (HIK.LN) price target to 770p from 715p to adjust for current FX rates and a slightly higher interest charge than previously anticipated. Notes Hikma has launched oncology injectable products in the Middle East and North Africa, and says this is a significant opportunity, given lower Injectable generic penetration. Adds the company continues to roll out Injectables in Europe, where the underlying business remains stable. Keeps the stock at buy. Shares +0.1% at 692p. (michele.maatouk@dowjones.com) Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com (END) Dow Jones Newswires June 23, 2010 04:16 ET (08:16 GMT)